{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-045157","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.071945+00:00","generated_at":"2026-05-17T03:34:18.017555+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"low","headline":"C4 Therapeutics posts Phase 1 cemsidomide data in RRMM; terminates TD Cowen ATM prospectus","bullets":["Posted Phase 1 data for cemsidomide + dex in relapsed/refractory multiple myeloma; presentation on IR website.","Terminated sales agreement prospectus with TD Cowen effective Oct 16, 2025; underlying agreement remains in effect.","Previously issued 3,769,483 shares under TD Cowen ATM for gross proceeds of $9.6M as of June 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-045157","json":"https://secwatch.observer/filing/0001628280-25-045157.json","markdown":"https://secwatch.observer/filing/0001628280-25-045157.md","text":"https://secwatch.observer/filing/0001628280-25-045157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025045157/0001628280-25-045157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025045157/cccc-20251016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:34:18.017555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}